Dataset Information

Ceritinib Functional Proteomics

ABSTRACT: To elucidate the mechanism of action (MoA) of ceritinib’s antiproliferative activity in these cells, we applied a systems approach combining both chemical and phosphoproteomics to gain a global view of ceritinib’s target profile and network-wide phosphorylation changes following ceritinib treatment.

INSTRUMENT(S): LTQ Orbitrap, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung

SUBMITTER: Brent Kuenzi

LAB HEAD: Uwe Rix

PROVIDER: PXD007137 | Pride | 2018-01-12

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20150216_Rix_PD418.RAW	Raw
	20150216_Rix_PD418.RAW (F031615).mzid_20150216_Rix_PD418.RAW_(F031615).pride.mgf.gz	Mzid
	20150216_Rix_PD418.RAWF031615.mzid.gz	Mzid
	20150216_Rix_PD418.RAWF031615.mzid_20150216_Rix_PD418.RAW_F031615.MGF	Mzid
	20150216_Rix_PD419.RAW	Raw

Items per page:

1 - 5 of 312

Publications

Polypharmacology-based ceritinib repurposing using integrated functional proteomics.

Kuenzi Brent M BM Remsing Rix Lily L LL Stewart Paul A PA Fang Bin B Kinose Fumi F Bryant Annamarie T AT Boyle Theresa A TA Koomen John M JM Haura Eric B EB Rix Uwe U

Nature chemical biology 20171009 12

Targeted drugs are effective when they directly inhibit strong disease drivers, but only a small fraction of diseases feature defined actionable drivers. Alternatively, network-based approaches can uncover new therapeutic opportunities. Applying an integrated phenotypic screening, chemical and phosphoproteomics strategy, here we describe the anaplastic lymphoma kinase (ALK) inhibitor ceritinib as having activity across several ALK-negative lung cancer cell lines and identify new targets and netw ...[more]

PMID: 28991240

Similar Datasets

Project description:Human pancreatic stellate cells (HPSCs) are an essential stromal component and are the mediators of pancreatic ductal adenocarcinoma (PDAC) progression. Small extracellular vesicles (sEVs) are membrane-enclosed nanoparticles released from stellate cells adjacent to the PDAC. sEVs are believed to play a key role in cell-cell communications and may play a critical role in disease progression. The role of membrane proteins of HPSC sEVs in the PDAC tumor microenvironment is unclear and to date, there has not been a quantitative proteomic comparison of sEVs from normal pancreatic stellate cells (HPaStec) and from PDAC-associated stellate cells (HPSCs). We hypothesized there would be differences in sEVs secretion and membrane protein expression between the 2 conditions that might contribute to PDAC biology. To test these hypotheses, we isolated sEVs using ultracentrifugation followed by characterization by electron microscopy and Nanoparticle Tracking Analysis. HPSCs secreted more sEVs compared to HPaStec, and these sEVs were enriched with exosomal markers, which was confirmed by Western blotting and flow cytometry. HPSC-sEVs also restore the activation of normal stellate cells. Next, we showed that intact membrane-associated proteins may be essential for sufficient uptake of stellate cell sEVs by both normal epithelial and cancer cells. Importantly, we demonstrated that stellate cells in general modulate the cellular proliferations of pancreatic cancer cells although stellate cell sEVs did not change the proliferation of cancer cells. We then compared sEV proteins isolated from HPSCs and HPaStecs cells using liquid chromatography–tandem mass spectrometry. Most of the 1,481 protein groups identified were shared with the exosome database, ExoCarta (http://exocarta.org/; curated by the Mathivanan Lab). Eighty-seven protein groups were differentially expressed (selected by 2-fold difference and adjusted P value ≤ 0.05) between HPSC and HPaStec sEVs. HPSC sEVs contained dramatically more CSE1L, a poor prognostic marker for pancreatic cancer. In conclusion, our findings using mass spectrometry–based proteomics may direct further studies to understand the biology and role of protein composition of HPSC sEVs in PDAC progression or to develop novel strategies based on delivery of exosome cargo to PDAC tumor cells.